The incidence of cutaneous squamous cell carcinoma (cSCC) is rising worldwide. We have examined the role of complement components in the progression of cSCC. Analysis of cSCC cell lines (n ¼ 8) and normal human epidermal keratinocytes (n ¼ 11) with whole transcriptome profiling (SOLiD), quantitative real-time reverse transcriptase-PCR, and western blotting revealed marked overexpression of complement factor I (CFI) in cSCC cells. Immunohistochemical analysis for CFI in vivo showed stronger tumor cell-specific labeling intensity in invasive sporadic cSCCs (n ¼ 83) and recessive dystrophic epidermolysis bullosa-associated cSCCs (n ¼ 7) than in cSCC in situ (n ¼ 65), premalignant epidermal lesions (actinic keratoses, n ¼ 64), benign epidermal papillomas (seborrheic keratoses, n ¼ 39), and normal skin (n ¼ 9). The expression of CFI was higher in the aggressive Ha-rastransformed cell line (RT3) than in less tumorigenic HaCaT cell lines (HaCaT, A5, and II-4). The expression of CFI by cSCC cells was upregulated by IFN-g and IL-1b. Knockdown of CFI expression inhibited proliferation and migration of cSCC cells and resulted in inhibition of basal extracellular signal-regulated kinase (ERK) 1/2 activation. Knockdown of CFI expression potently inhibited growth of human cSCC xenograft tumors in vivo. These results provide evidence for the role of CFI in the progression of cSCC and identify it as a potential therapeutic target in this nonmelanoma skin cancer.
INTRODUCTION
Nonmelanoma skin cancer is the most frequent cancer worldwide, and its incidence is increasing (Rogers et al., 2010) . Approximately 20% of nonmelanoma skin cancers are invasive cutaneous squamous cell carcinomas (cSCCs), which have potential for recurrence and metastasis. It has been estimated that the 5-year rate of metastasis for cSCC is 5% and that 20% of all skin cancer-related deaths are caused by cSCC (Tufaro et al., 2011) . The main risk factor for cSCC is solar UVR, and the other important risk factors are immunosuppression and chronic cutaneous ulcerations (Kivisaari and Kähäri, 2013) . Inflammation is an important feature in the progression of premalignant lesions, i.e., actinic keratoses (AKs) to invasive and metastatic cSCCs (Ratushny et al., 2012) .
The complement system has an important role in the activation of innate and acquired immunity. Complement is activated in a sequential manner via three distinct pathways--i.e., classical, lectin, or alternative pathway (Ricklin et al., 2010) . Activation of all three pathways leads to cleavage of C3 and C5 followed by the formation of membrane attack complex and eventually target cell lysis. Activation of the complement cascades is strictly controlled by soluble and cell surface bound inhibitory molecules, which protect host cells from complement-mediated destruction (Rutkowski et al., 2010a) .
Complement factor I (CFI) is a soluble 88 kDa serine protease, which is synthesized as a single polypeptide chain and processed to glycosylated 50 kDa heavy and 38 kDa light chains covalently linked by a disulfide bond (Goldberger et al., 1984) . CFI has an important role in the regulation of complement activation, as it can inhibit activation of all three pathways by cleaving activated C4b and C3b. CFI functions with cofactors complement factor H (CFH) (Schulze et al., 1993) , complement receptor type 1 (CD35), C4b-binding protein, and membrane cofactor protein (CD46) (Nilsson et al., 2011) . Normal human epidermal keratinocytes (NHEKs) have previously been shown to express complement components and inhibitors, including CFI (Dovezenski et al., 1992; Timar et al., 2007a) . In our recent study, we showed that cSCCs overexpress CFH, the other inhibitor of the alternative pathway (Riihilä et al., 2014) .
In this study, we have examined the role of CFI in the progression of cSCC. The results show marked overexpression of CFI by cSCC cells in culture and by tumor cells in invasive cSCCs in vivo. Moreover, the results show that CFI regulates proliferation and migration of cSCC cells and promotes growth of human cSCC xenografts in vivo. These results provide evidence for the role of CFI in the progression of cSCC and identify it as a potential therapeutic target in these cutaneous malignant tumors.
RESULTS

Overexpression of CFI in cSCC cells
The expression of complement system components in eight cSCC cell lines (five primary and three metastatic) and in primary human epidermal keratinocytes (NHEKs) from healthy skin of five individuals was first determined by oligonucleotide array-based (Affymetrix, Santa Clara, CA) expression profiling. The expression of most complement components was low in NHEKs, whereas significantly higher expression of mRNAs for complement components C1rl, C1r, C1s, and C3 and complement inhibitors FHL-1, CFH/CFHR1, and CFI was noted in cSCC cell lines (Figure 1a ). To verify these findings, next-generation-sequencing-based whole transcriptome expression profiling (SOLiD) of NHEK and cSCC cell lines was also performed. In general, the basal expression of mRNAs for the majority of complement system components, with the exception of C1r, C1s, and C3, was low in NHEK ( Figure 1b) . In contrast, the levels for mRNAs of certain complement components (C1r, C1s, C3, CFB, and CFD) and complement inhibitors (CFH and CFI) were clearly elevated in cSCC cells as compared with NHEKs ( Figure 1b ). In addition, the levels of CFI mRNA were higher in metastatic cSCC cell lines than in cell lines derived from primary cSCC. Analysis of CFI mRNA levels in NHEKs and cSCC cells by quantitative real-time PCR (qPCR) confirmed that the mean levels of CFI mRNA were significantly increased in the cSCC cell lines, as compared with NHEKs ( Figure 1c) .
Production of CFI by NHEKs and cSCCs was analyzed by western blotting of the cell lysates. Specific bands corresponding to CFI were noted most abundantly in cSCC cell cultures, as compared with NHEKs ( Figure 1d ). The expression of CFI by cSCC cells in vivo was also examined with immunohistochemistry (IHC) in xenograft tumors established with human cSCC cells (UT-SCC-7) in severe combined immunodeficient (SCID) mice. The expression of CFI was detected specifically in partially differentiated cSCC tumor cells in the xenografts (Figure 1e ).
Tumor cell-specific overexpression of CFI in cSCCs in vivo
To examine the expression of CFI during cSCC progression in vivo, tissue microarrays consisting of sporadic UV-induced invasive cSCCs (n ¼ 83), cSCCs of patients with RDEBSCC (n ¼ 7), cSCCs in situ (cSCCIS, n ¼ 65), and premalignant lesions (AK, n ¼ 64) were analyzed by IHC. Benign epidermal papillomas, i.e., seborrheic keratoses (SKs, n ¼ 39), and normal skin (n ¼ 9) were examined as controls.
The results showed marked tumor cell-specific staining for CFI in cSCCs (Figure 2a-c) and RDEBSCC (Figure 2d ). The staining intensity was scored moderate ( þ þ ) (Figure 2a ) and strong ( þ þ þ ) (Figure 2b-d) . In general, weaker staining intensity for CFI was detected in cSCCIS ( Figure 2h ) and AK ( Figure 2g ). Epidermal keratinocytes in SK (Figure 2f ) and in normal skin ( Figure 2e ) were mainly negative ( À ) or weakly positive ( þ ) for CFI. Semiquantitative analysis of the immunostainings revealed that the proportion of tumor sections presenting strong staining ( þ þ þ ) for CFI was significantly higher in cSCC and RDEBSCC groups, as compared with cSCCIS, AK, SK, and normal skin (Figure 2i ).
Overexpression of CFI in Ha-ras-transformed tumorigenic HaCaT cells
To further elucidate the role of CFI in the progression of cSCC, the expression of CFI was determined in immortalized nontumorigenic keratinocyte-derived cell line (HaCaT) lacking functional p53 and in three Ha-ras-transformed tumorigenic HaCaT-derived cell lines (A5, II-4, and RT3, Mueller et al., 2001) . As shown in Figure 3a , the expression of CFI mRNA was low in HaCaT, A5, and II-4 cells, whereas markedly higher levels of CFI mRNA were noted in RT3, the most aggressive ras-transformed tumorigenic HaCaT-derived cell line. Similarly, the production of CFI protein determined by western blotting was markedly upregulated in RT3 cells, as compared with other HaCaT-derived cell lines (Figure 3b ).
Regulation of CFI expression in cSCC and HaCaT cells by cytokines and growth factors
To examine the regulation of CFI expression, HaCaT and Haras-transformed HaCaT cell lines with different basal CFI expression were treated with cytokines and growth factors present in the cSCC tumor microenvironment. Subsequent analysis by qPCR showed that the low basal expression of CFI mRNA was upregulated by IFN-g and IL-1b in HaCaT cells, A5 and II-4 cells (Figure 3c ), as well as in two primary cSCC cell lines (UT-SCC-118 and -12A, Figure 3d ). In contrast, in RT3 cells the high basal expression of CFI was not further upregulated by IL-1b, but downregulation of CFI mRNA levels was noted in cultures treated with IFN-g and transforming growth factor-b1 (Figure 3c ).
CFI regulates cSCC cell proliferation and migration
To elucidate the functional role of CFI in cSCC cells, specific small interfering RNA (siRNA) was utilized to knockdown CFI expression (Figure 4a) . A significant reduction in the number of viable cells was detected at 48 and 72 hours time points in CFI siRNA-transfected cSCC (UT-SCC-59A) cultures, as compared with control siRNA-transfected cultures (Figure 4b ). Similar effect of CFI knockdown on proliferation was detected with another cSCC cell line (UT-SCC-118) (Figure 4b ). Potent inhibition of ERK1/2 activation was also detected 72 hours after CFI knockdown in UT-SCC-118 cells (Figure 4c ). Furthermore, significant inhibition of migration of cSCC cells (UT-SCC-59A and -118) was noted in CFI siRNA-transfected cultures 16 and 24 hours after wounding (Figure 4d ). cultures were transfected with CFI and control siRNA and incubated for 72 hours. Thereafter, the transfected cells (5 Â 10 6 ) were injected subcutaneously into the back of SCID/SCID mice, and the growth of xenografts was followed weekly. Interestingly, growth of cSCC xenografts was significantly suppressed by knockdown of CFI expression, as
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Prim. cSCC compared with control siRNA-transfected cSCC cells ( Figure 5a ). Extended incubation of siRNA-transfected UT-SCC-7 cultures in parallel showed that knockdown of CFI mRNA persisted up to 15 days (data not shown).
Histological analysis of the xenografts harvested at day 18 after implantation revealed that tumors established with CFI siRNA were less cellular than those in the control siRNA group (Figure 5b ). The Ki-67-positive proliferating cells were detected close to the tumor margin in xenografts in both groups ( Figure 5b ). However, the number of Ki-67-positive cells was significantly lower in CFI siRNA xenografts than in control siRNA xenografts (Figure 5b and c). To investigate the effect of CFI knockdown on complement activation, cSCC xenografts were labeled with IHC using an antibody against C3b. Positive staining for C3b was detected on tumor cell surface in cell clusters in the invasive edge of xenografts and the number of positive cells, and the staining intensity was stronger in CFI siRNA tumors, as a marker for C3b accumulation. Moreover, IHC with antibody against proinflammatory cytokine tumor necrosis factor-a (TNF-a) showed stronger staining intensity and elevated number of positive cells in CFI siRNA tumors, as compared with the control siRNA xenografts providing further evidence for complement activation.
DISCUSSION
The complement system is an integral part of host defense. It can be activated via classical, lectin, or the alternative pathway (Zipfel and Skerka, 2009 ). Of these, the classical pathway (a-h) Complement factor I (CFI) antibody was used to stain sections of tissue microarray blocks containing cSCC (n ¼ 83), recessive dystrophic epidermolysis bullosa (RDEBSCC; n ¼ 7), cSCCIS (cSCC in situ, Bowen's disease; n ¼ 65), premalignant lesions (actinic keratosis, AK; n ¼ 64), benign epidermal papillomas (seborrheic keratosis, SK; n ¼ 39), and normal skin (n ¼ 9). Moderate (a) or strong (b, c) cytoplasmic staining for CFI is detected in cSCC cells. (d) Strong cytoplasmic staining for CFI was also detected in tumor cells in cSCC associated with RDEBSCC. Staining for CFI was absent in normal skin (e), SK (f), or AK (g) and weak in most cSCCIS (h) sections. Scale bars ¼ 200 mm.
(i) Semiquantative analysis of CFI staining in normal skin, SK, AK, cSCCIS, cSCC, and RDEBSCC tissue sections. Tumor cell-specific immunostaining for CFI was scored as negative ( À ), weak ( þ ), moderate ( þ þ ), and strong ( þ þ þ ). The percentage of tumors with strong tumor cell-specific staining in cSCCs is significantly higher than in normal skin, SK, AK, or cSCCIS sections (all Po0.001; the w 2 -test).
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Complement Factor I in Cutaneous Squamous Cell Carcinoma is activated by antibodies and the lectin pathway by contact with carbohydrates on microbial surfaces, whereas the alternative pathway is continuously and spontaneously activated. Activation of all pathways takes place in a sequential manner, and this process is strictly controlled by soluble and membrane bound inhibitors, which protect cells in host tissues from damage (Zipfel and Skerka, 2009) . CFI is a complement inhibitor, which together with its cofactors has an important role in regulating the activation of all three pathways. CFI is a serine protease with a highly restricted substrate specificity. It cleaves the a'-chain of activated C3b with cofactors CFH, complement receptor 1 (CD35), and membrane cofactor protein (CD46) (Nilsson et al., 2011) . CFI also inactivates C4b by cleavage of the a'-chain with the cofactor C4b-binding protein, membrane cofactor protein, or complement receptor 1. Furthermore, C4b-binding protein can also act as a cofactor for inactivation of C3b (Nagasawa and Stroud, 1977) . CFI is synthesized mostly in the liver, and it is secreted as a single 88 kDa protein. This is then cleaved by furin to yield the mature proteolytically active CFI, which consists of disulfide-linked heavy chain (50 kDa) and light chain (38 kDa) found in serum. CFI has no endogenous inhibitor, but its activity in vivo is regulated by the supply of substrates (Nilsson et al., 2011) . CFI is also produced by keratinocytes (Timar et al., 2007b) , skin fibroblasts (Vyse et al., 1996) , myoblasts (Schlaf et al., 2001) , monocytes (Whaley, 1980) , and endothelial cells .
The results of the present study show that tumor cells of cSCCs produce CFI in culture and in vivo. The expression of the mRNAs for CFI as well as production of CFI at the protein level was elevated in most cSCC cell lines studied, whereas the basal expression of CFI in NHEKs was low or negative. IHC analysis of human cSCC xenograft tissue showed that CFI was expressed by cSCC tumor cells in vivo. Further investigation of CFI expression in vivo was carried out by IHC analysis of tissue microarrays consisting of a large panel of cSCCs, cSCCIS, AK, SK, and normal skin. Results of IHC analysis revealed that CFI was specifically expressed by tumor cells in cSCCs. In addition, the IHC analysis of RDEBSCCs, an aggressive form of cSCC, revealed strong tumor cellassociated CFI staining. Interestingly, strong or moderate cytoplasmic CFI staining was detected in the majority of the cSCC tumors, whereas no CFI-negative tumors were noted in cSCC or RDEBSCC groups. CFI staining was clearly stronger in cSCC tumor sections than in cSCCIS and AK, indicating that the expression is induced at the invasive stage of the cSCC progression. In contrast, staining for CFI was negative or weak in the majority of normal skin and in benign epidermal papillomas (SK). On the basis of these observations, we propose CFI as a biological marker for the progression of cSCC.
Analysis of Ha-ras-transformed HaCaT cells representing different stages of cSCC progression (Mueller et al., 2001) showed that basal CFI expression was low in parental HaCaT ) for 24 hours. CFI mRNA levels were determined by qPCR and corrected for the levels of b-actin mRNA in the same samples. Statistical analysis was carried out with the Mann-Whitney U-test.
Complement Factor I in Cutaneous Squamous Cell Carcinoma cells and in the benign tumorigenic Ha-ras-transformed cell line (A5) and in the low tumorigenic cell line (II-4) but markedly higher in the invasive tumorigenic Ha-rastransformed HaCaT cell line (RT3). These results indicate that inactivation of p53 and activation of ras signaling are not alone sufficient for induction of basal CFI expression, but additional genomic alterations are required. Our results also show that CFI expression in cSCC cells with low basal expression is susceptible to stimulation by IL-1b, IFN-g, and transforming growth factor-b1. These results are in accordance with previous observation showing that inflammatory cytokines, e.g., IFN-g, upregulate expression of CFI by keratinocytes (Timar et al., 2007b) . However, it appears that in the Ha-ras-transformed HaCaT cell line (RT3) with high basal expression of CFI, the expression is not further upregulated by these cytokines and growth factors.
We have recently reported that the expression of certain complement components and inhibitors is elevated in cSCC cells, as compared with keratinocytes (Riihilä et al., 2014) . These observations are supported by the results of the present study obtained using next-generation-sequencing based expression profiling. Overexpression of C3, CFB, CFH, and CFI was noted in cSCC cell lines, as compared with NHEK. These findings suggest that cSCC cells can produce and The number of viable cells (UT-SCC-59A and -118) was determined 24, 48, and 72 hours after siRNA transfection using the WST-1 assay (n ¼ 5-8 parallel wells; ***Po0.001, Student's t-test). (c) The levels of phosphorylated extracellular signal-regulated kinase (ERK)1/2 (p-ERK1/2), total ERK1/2, phosphorylated p38 (p-p38), and total p38 were analyzed by western blotting 72 hours after siRNA transfection. p-ERK1/2 and p-p38 blots were analyzed densitometrically and corrected for the levels of total ERK1/2 and p38, respectively (below the blots).
(d) Primary cSCC cells (UT-SCC-59A and -118) were transfected with CFI and control siRNA and incubated for 48 hours. The cultures were then treated with 1 mM hydroxyurea for 6 hours to inhibit cell division. A scratch was generated in the cell monolayer by pipet tip, and incubation was continued in DMEM with 1% fetal calf serum and 0.5 mM hydroxyurea for 24 hours. Representative images of the experiment are shown at time points 0, 16, and 24 hours (upper panel). The quantitation of relative migration rates is shown in lower panel (n ¼ 3; Po0.001, Mann-Whitney U-test).
activate components of the complement system, and this way may promote inflammation in the tumor microenvironment. It is likely, that tumor cells can utilize complement inhibitors for immune evasion (Gorter and Meri, 1999) . Expression of CFI by tumor cells has been shown in glioma (Gasque et al., 1992) , non-small-cell lung cancer (Okroj et al., 2008) , and rhabdomyosarcoma (Legoedec et al., 1995) . The results of the present study, together with our previous observations (Riihilä et al., 2014) , provide evidence that cSCC cells can protect themselves from complement-mediated cell killing by producing complement inhibitors CFH and CFI. This notion is supported by the observation that CFI knockdown results in accumulation of C3b in the cell surface of tumor cells in cSCC xenografts (Figure 5b) . The results of this study also provide evidence for two, to our knowledge previously unreported, functions of CFI, i.e., regulation of cell proliferation and migration, which are especially relevant in cancer growth and invasion.
Interestingly, potent inhibition of ERK1/2 activation in cSCC cells in culture was noted following knockdown of CFI expression. Similar effect has been reported previously in cultured cSCC cells with CFH, another important soluble inhibitor of complement and cofactor for CFI (Riihilä et al., 2014) . Together these observations provide evidence that inhibition of the alternative pathway of complement can regulate proliferation and survival of malignant cells. These observations are also supported by our results showing that knockdown of CFI in cSCC cells results in significant inhibition of cSCC cell implantation and subsequent tumor growth in vivo in the xenograft model in SCID mice. The exact mechanism for the mitogenic effect of the CFI is not known, but it may involve generation of a mitogenic fragment from C3 by CFH and CFI (Vetvica et al., 1993) . Our results also show that CFI knockdown results in accumulation of C3b on the tumor cell surface in cSCC xenografts. Further evidence for complement activation is also provided by stimulation of TNF-a ) were then implanted subcutaneously into the back of SCID/SCID mice, and the growth of tumors was measured as indicated. *Po0.05, ***Po0.001, Student's t-test (n ¼ 8). (b) Xenografts were harvested after 18 days, and the histology was analyzed in tumor sections stained with hematoxylin and eosin (HE). Ki-67, C3b, and tumor necrosis factor-a (TNF-a) were detected in xenografts by immunohistochemistry, and Mayer's hematoxylin was used as counterstain. The proliferating cells were identified by Ki-67. The staining for C3b in CFI siRNA group was stronger than in the control group, and the staining was specifically noted on cell surface and in tumor cell cytoplasm in the invasive edge of the tumor. Specific staining for TNF-a was detected in the cytoplasm of cSCC tumor cells. The staining intensity for TNF-a was more abundant, and there were positively stained cells in wider areas in CFI siRNA xenografts compared with control siRNA xenografts. Representative stainings from each group are shown. (c) The relative number of Ki-67-positive cells was determined by counting 300-500 cells at Â 20 magnification in all tumor sections using digital imaging. Statistical significance between control and CFI siRNA groups was determined by the Mann-Whitney U-test (n ¼ 6). Scale bars ¼ 200 mm. production in xenografts in response to CFI knockdown. It is therefore possible that complement-mediated cell destruction is at least in part responsible for reduced growth of CFI siRNA xenografts. These results are in accordance with previous observations showing that, although the activation of the classical pathway of complement is defective in SCID mice due to lack of immunoglobulins, the activation of the alternative pathway examined in this study is intact (Reca et al., 2007) . However, it is also possible that CFI as a serine protease may have additional functions on tumor growth beyond regulation of complement activation (Rutkowski et al., 2010b) .
Taken together, our results demonstrate tumor cellassociated overexpression of the important inhibitor of the complement system, CFI in cSCCs. These results provide evidence that this complement inhibitor has an important role in the progression of cSCCs, possibly by allowing tumor cells escape from complement attack. In addition, our results show that CFI promotes cSCC cell proliferation and migration and promotes cSCC growth in vivo. In conclusion, these results suggest that CFI has an important role in the progression of cSCC and identify it as a therapeutic target in this form of nonmelanoma skin cancer.
MATERIALS AND METHODS
Ethical issues
The use of archival tissue specimens and collection of normal skin and cSCC tissues was approved by the Ethics Committee of the Hospital District of Southwest Finland. The study was carried out according to 'the Declaration of Helsinki Principles' with the approval of Turku University Hospital. Written informed consent of all patients was obtained before surgery.
Cell cultures
Primary human epidermal keratinocytes (NHEK-PC) were acquired from PromoCell (Heidelberg, Germany). In addition, NHEKs were established from skin samples obtained from mammoplasty (n ¼ 11). Human cSCC cell lines (n ¼ 8) were established from the cSCCs at the time of operation (Farshchian et al., 2011) . Five of these were derived from primary cSCCs and three from metastases (UT-SCC-7, -59A, and -115). The spontaneously immortalized non-tumorigenic human keratinocyte-derived cell line (HaCaT, Boukamp et al., 1988) and three Ha-ras-transformed tumorigenic HaCaT cell lines (A5, II-4, and RT3, Boukamp et al., 1990) were kindly provided by Dr Norbert Fusenig (Deutsche Krebsforschungszentrum, Heidelberg, Germany). A5 cells form benign, II-4 cells low-grade malignant and RT3 cells high-grade malignant tumors in vivo in nude mice (Mueller et al., 2001) . Cells were cultured as previously described (Riihilä et al., 2014) . For cytokine and growth factor treatment, UT-SCC-118, -12A, and HaCaT cell lines were maintained in serum-free DMEM for 24 hours and then treated with IL-1b (10 ng ml 
Gene expression profiling
The expression of complement system components in NHEKs (n ¼ 5) and in eight cSCC cell lines (five primary and three metastatic) was determined with Affymetrix Human Genome U133 Plus 2.0 array (Affymetrix) as previously described (Riihilä et al., 2014) . Whole transcriptome libraries of NHEKs (n ¼ 4) and cSCC cell lines (n ¼ 8) were prepared with the SOLiD Whole Transcriptome Analysis Kit (Applied Biosystems, Foster City, CA) at Finnish Microarray and Sequencing Centre, Turku Center for Biotechnology, Turku, Finland. The samples were processed with the SOLiD 3Plus instrument (35 bp read length, NHEKs and SCCs). The colorspace reads were aligned against the human reference genome (GRCh37 assembly for NHEKs and SCCs) using the standard whole transcriptome pipeline and the colorspace alignment tool (Applied Biosystems). The quantile-to-quantile adjustment (R/Bioconductor package edgR) was used to normalize the data (Robinson et al., 2010) .
qPCR
Total RNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen, Chatsworth, CA). cDNA was synthesized using 1 mg of total RNA, treated with RQ1 DNase (M610A, Promega ), random primers (C118A, Promega), M-MLV reverse transcriptase (M531A, Promega), and RNase H minus polymerase (M368B, Promega). qPCR analysis of cDNA samples was performed with specific primers and fluorescent probes, as previously described (Stokes et al., 2010) . For CFI, the following primers and probe were used:
Forward primer 5 0 -CTCAGCAGAGACAAAGAC-3
Primers and probes for b-actin and GAPDH have been described previously (Riihilä et al., 2014) . Samples were analyzed in duplicate. The range of the threshold cycle values was o5% of the mean in each measurement. The results for CFI mRNA were corrected for expression of b-actin or GAPDH mRNA in the same samples.
Western blot analysis
The production of CFI by NHEKs, cSCC, and HaCaT cell lines was determined by western blotting of cell lysates both under reducing and nonreducing conditions using mouse monoclonal anti-CFI antibody (1:500; clone OX-21, Novus Biologicals, Littleton, CO). Equal protein loading was confirmed with mouse monoclonal anti-bactin antibody (A 1978; Sigma Aldrich; Riihilä et al., 2014) .
Tissue samples and immunohistochemistry
Altogether, 260 formalin-fixed paraffin-embedded tissue samples were accessed from the archives of the Department of Pathology, Turku University Hospital. These included sporadic UV-induced cSCC (n ¼ 83; mean age 79 years, range 45-102 years), cSCCIS (Bowen's disease; n ¼ 65; mean age 79 years, range 59-95 years), AK (n ¼ 64; mean age 78 years, range 58-95 years), seborrheic keratoses (n ¼ 39; mean age 66 years, range 26-95 years), and normal skin (n ¼ 9). In addition, RDEBSCCs (n ¼ 7; mean age 33 years, range 12-56 years) were used (Kivisaari et al., 2008) . Tissue microarray blocks were generated of these samples as described (Kononen et al., 1998) . The sections were stained with mouse monoclonal anti-CFI antibody (clone OX-21, Novus Biologicals), diluted (1:150) in phosphatebuffered saline containing 1.5% horse serum, as previously described (Kivisaari et al., 2008; Farshchian et al., 2011) . For negative control stainings, the primary antibody was replaced with phosphate-buffered saline. The intensity of cytoplasmic staining was scored as negative ( À ), weak ( þ ), moderate ( þ þ ), or strong ( þ þ þ ) by two independent observers (PR and MK).
siRNA knockdown of CFI expression
For siRNA knockdown of CFI, cSCC cells were grown to 50% confluency and transfected with siRNA targeting CFI mRNA or with negative control siRNA (120 nM; Qiagen, Hilden, Germany) using siLentFect Lipid Reagent (Bio-Rad Laboratories, Hercules, CA), as previously described (Kivisaari et al., 2010) . Cells were harvested 24, 48, and 72 hours or 6, 10, and 15 days after transfection. The levels of CFI mRNA were determined by qPCR and CFI protein levels by western blotting.
Cell proliferation cSCC cells were transfected with CFI siRNA or with negative control siRNA (120 nM). Twenty-four hours after transfections, cells (1.0 Â 10 4 cells per well) were seeded on 96-well plates. The number of viable cells was determined with WST-1 cell proliferation reagent (Roche Diagnostics, Mannheim, Germany). In each time point, 5-8 parallel wells were analyzed with two cSCC cell lines (UT-SCC-59A and -118). Activation of ERK1/2 and p38 was determined by western blotting of the cell lysates with specific antibodies for phospho-ERK1/ 2 and phospho-p38 and for total ERK1/2 and p38 (all from Cell Signaling Technology, Beverly, MA).
Cell migration
Cells were transfected with CFI siRNA or negative control siRNA (120 nM) and incubated for 48 hours. To inhibit cell division, cells were then treated with 1 mM hydroxyurea (Sigma Aldrich) in DMEM with 1% fetal calf serum for 6 hours. A scratch was created with a pipet tip in the cell monolayer, and incubation was continued in DMEM with 10% fetal calf serum and 0.5 mM hydroxyurea for 24 hours. Migration was analyzed with Olympus IX70 inverted microscope (Olympus Optical, Tokyo, Japan), and the cell-free area was measured in four areas, in one well with ImageJ software (Schneider et al., 2012) and in three parallel wells with two cSCC cell lines (UT-SCC-59A and -118).
Human cSCC xenografts
Establishment of human cSCC xenografts was performed using a highly tumorigenic cSCC cell line (UT-SCC-7), as described previously (Ala-aho et al., 2004; Leivonen et al., 2006; Junttila et al., 2007) . All experiments with mice were carried out with permission of the animal test review board of the Southern Finland according to institutional guidelines. UT-SCC-7 cells were transfected with CFI or control siRNA and incubated for 72 hours. Subsequently, 5 Â 10 6 cells in 100 ml of phosphate-buffered saline were injected subcutaneously into the back of SCID female mice (CB17/Icr-Prkdc scid / IcrIcoCrl) (n ¼ 8 for each group) (Charles River Laboratories, Wilmington, MA). The size of tumors was measured once a week, and their volume calculated as p4/3((length þ width)/4)3 (Watt et al., 2011) . In the end, tumors were harvested and processed for histological analysis and IHC, as previously described (Junttila et al., 2007) . Proliferating cells were detected by Ki-67 immunostaining using monoclonal antibody for human Ki-67 (MIB-1; DAKO, Glostrup, Denmark) with Mayer's hematoxylin as counterstain. The relative number of Ki-67-positive cells was determined by counting 300-500 cells at 20 Â magnification from all sections using ImageJ Software. Polyclonal goat anti-C3 antibody, which specifically detects C3b (Calbiochem, La Jolla, CA), and rabbit polyclonal antibody against human TNF-a (H-156; Santa Cruz Biotechnology, Dallas, TX) were used for immunostaining of tumors with Mayer's hematoxylin as counterstain.
Statistical analysis
The statistical analyses were performed using the SPSS software (IBM SPSS, Armonk, NY). The significance of differences between sample groups for oligonucleotide array, whole transcription profiling, qPCR, cell proliferation and cell migration assays, and xenograft analysis was determined with the Mann-Whitney U-test or Student's t-test, as indicated. Comparison of IHC staining intensity was performed with the w
